Overview

A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension

Status:
Completed
Trial end date:
2018-02-18
Target enrollment:
Participant gender:
Summary
An open label study to assess the safety and efficacy of tocilizumab in group 1 pulmonary arterial hypertension patients
Phase:
Phase 2
Details
Lead Sponsor:
Papworth Hospital NHS Foundation Trust
Collaborators:
National Institute for Health Research, United Kingdom
Roche Pharma AG